Détails du produit
Synonyms
CLU, Clusterin, AAG4, APOJ, CLI, KUB1, SGP-2, SP-40, TRPM2
Source
Human Clusterin, His Tag (CLU-H5227) is expressed from human 293 cells (HEK293). It contains AA Asp 23 - Glu 449 (Accession # NP_001822.3).
Predicted N-terminus: Asp 23
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 50.9 kDa. The protein migrates as 32-40 kDa under reducing (R) condition (SDS-PAGE).
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE

Human Clusterin, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Bioactivity-SPR

Human Clusterin, His Tag (Cat. No. CLU-H5227) immobilized on CM5 Chip can bind Human VLDL R, His Tag (Cat. No. VLR-H5227 ) with an affinity constant of 265 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Protocol
Avis des utilisateurs Publier un commentaire

Introduction de fond
Progrès de frontière
- Nom anglais:
Clusterin
- Catégorie:
- Nombre de médicaments répertoriés:
0 Détails
- Nombre de médicaments cliniques:
1 Détails
- Étape de développement la plus élevée:
Phase 2 Clinical



















